Download PDF: Long-Acting Reversible Contraception Long-acting reversible contraception (LARC) is defined as methods of birth control that provide effective contraception for an extended period of time without requiring user action and therefore not depending on patient compliance. The 2005 NICE guidelines state that all currently available LARC methods are the most cost effective methods and […]
New Long-Acting Reversible Contraception Option
June 1, 2014 by Leave a Comment
Download PDF: New Long-Acting Reversible Contraception Option Jaydess is a new option in intra-uterine contraception which adds to the other available option Mirena. The rationale for the development of Jaydess is a shorter maximum duration of use and a lower daily levonorgestrel release rate, which result in a smaller reservoir and therefore an easier and […]
Ganfort Single Dose
June 1, 2014 by Leave a Comment
Company: Allergan Ltd. Legal category: Prescription. GMS. Prohibited in specific sports. Active ingredient: Bimatoprost 0.3mg/ml, timolol (as maleate) 5mg/ml. Description: Colourless eye drops. Presentation: 0.4ml vials-30, €24.25. Indication: Reduction of intraocular pressure (IOP) in open-angle glaucoma or ocular hypertension insufficiently responsive to topical β-blockers or prostaglandin analogues. Pharmacology: Bimatoprost is a synthetic prostamide, and reduces […]
Ketovite
June 1, 2014 by Leave a Comment
Company: Essential Pharmaceuticals Ltd. Legal category: OTC. GMS. Sport permitted. Active ingredients: Tablets: Thiamine hydrochloride 1mg, riboflavin 1mg, pyridoxine hydrochloride 0.33mg, nicotinamide 3.3mg, calcium pantothenate 1.16mg, ascorbic acid 16.6mg, all-rac-Alpha-Tocopheryl acetate 5mg, inositol 50mg, biotin 0.17mg, folic acid 0.25mg, acetomenaphthone 0.5mg. Liquid: Vitamin A 2500IU, ergocalciferol 400IU, cyanocobalamin 12.5mcg, choline chloride 150mg per 5ml. Description: […]
Losec Control
June 1, 2014 by Leave a Comment
Company: Bayer Ltd. Legal category: OTC. Sport permitted. Active ingredient: Omeprazole 20mg. Description: Gastro-resistant, pink, oblong, biconvex film-coated tablet marked with symbol on one side and 20mg on reverse. Presentation: 7, €5.19; 14, €8.99. Indications: Treatment of reflux symptoms (e.g. heartburn, acid regurgitation) in adults. Pharmacology: Omeprazole is a proton pump inhibitor that suppresses gastric […]
Spedra ▼
June 1, 2014 by Leave a Comment
Company: A. Menarini Pharmaceuticals Ireland Ltd. Legal category: Prescription. GMS pending. Sport permitted. Active ingredient: Avanafil 50mg, 100mg, 200mg. Description: Pale yellow oval tablets marked 50, 100 or 200 on one side, respectively. Presentation: 50mg-4, €12.00; 100mg-4, €16.00, 200mg-4, €24.00. Indication: Treatment of erectile dysfunction (ED). Pharmacology: Avanafil is a highly selective and potent, reversible […]
Trospium
June 1, 2014 by Leave a Comment
Company: Glenmark Generics. Legal category: Prescription. GMS. Sport permitted. Active ingredient: Trospium chloride 20mg. Description: Brownish yellow to light brown round, biconvex film-coated tablets marked L on one side and l on reverse. Presentation: 60, €9.86. Indications: Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive […]
Hayfever Policy (Glucocorticosteroid Injections)
June 1, 2014 by Leave a Comment
Therapeutic Use Exemption (TUE) Committee Policy on Glucocorticosteroid Injections for Hay Fever (updated 25th April 2014) Depo-Medrone (Methylprednisolone) and Kenalog* (Triamcinolone) administered by intra-muscular injection as treatment for hay fever are prohibited in sport and therefore their use requires the athlete and their physician to strictly adhere to the TUE Policy. The TUE Policy is […]
Medicines Subject to Additional Monitoring – Update
June 1, 2014 by Leave a Comment
Information on the introduction of additional monitoring requirements for certain medicinal products for which there may be limited data/experience (e.g. with long term use), to support prompt identification of any new safety hazards and to allow appropriate regulatory action to initiated promptly was provided in the 50th and 53rd editions of the IMB Drug Safety […]
Loading ...
